Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease. In recent years, researchers have found that cysteine-rich angiogenic inducer 61 (Cyr61, also known as CCN1) has a potential role in reducing portal inflammation in patients with PBC. This study aimed to explore the relationship between Cyr61 and PBC to provide new ideas and an experimental basis for the clinical treatment of PBC.
Methods: After induction of the overexpression of Cyr61 in a mouse model of PBC using recombinant adenovirus, hematoxylin and eosin staining and pathological scores were used to indicate intrahepatic inflammation and bile duct damage. Real-time PCR was used to detect changes in inflammation-related cytokines in the liver. To further study the mechanism, we assessed whether Cyr61 protects bile duct epithelial cells from cytotoxic effects.
Results: Serum and hepatic Cyr61 levels were increased in the murine model of PBC. Overexpression of Cyr61 alleviated hepatic inflammation and bile duct injury in vivo. Cyr61 inhibited the cytotoxic effects of CD8 T cells by acting on biliary epithelial cells (BECs) in vitro.
Conclusion: Our results provide novel insight into the pathogenesis of PBC and suggest that Cyr61 plays a dominant role in the cytotoxic effects on BECs in PBC. Consequently, therapeutic strategies targeting Cyr61 could be a potent therapy for PBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11596-021-2458-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.
Nat Rev Cancer
September 2025
Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Neurotoxicity is a common and potentially severe adverse effect from conventional and novel cancer therapy. The mechanisms that underlie clinical symptoms of central and peripheral nervous system injury remain incompletely understood. For conventional cytotoxic chemotherapy or radiotherapy, direct toxicities to brain structures and neurovascular damage may result in myelin degradation and impaired neurogenesis, which eventually translates into delayed neurodegeneration accompanied by cognitive symptoms.
View Article and Find Full Text PDFThe molecular blueprint of targeted radionuclide therapy.
Nat Rev Clin Oncol
September 2025
German Cancer Consortium (DKTK), Partner Site Essen, Essen, Germany.
Targeted radionuclide therapy (TRT) is a cutting-edge treatment approach in oncology that combines the molecular precision of targeted agents with the effect of radiotherapy to selectively deliver cytotoxic radiation to cancer cells. Research efforts from the past few decades have led to a diverse molecular landscape of TRT and have provided lessons for further rational development of targeted radiopharmaceuticals and expansion of the clinical applications of this treatment modality. In this Review, we discuss TRT in the context of therapeutic approaches currently available in oncology, describe the broad range of established and emerging targets for TRT including innovative approaches to exploit vulnerabilities presented by the tumour microenvironment, and address the challenges for clinical translation and molecular optimization.
View Article and Find Full Text PDFSynthesis and preliminary biological evaluation of novel steroidal compounds as antibacterial agents.
Steroids
September 2025
Department of Chemical Sciences, University of Naples Federico II, Naples I-80126, Italy.
Antimicrobial resistance is currently one of the most serious and alarming threats to human health; therefore, the identification of novel antimicrobial agents is a compelling need. Recently, we identified the heterocyclic steroid PYED-1 as a novel promising antibacterial and antibiofilm agent. In an effort to broaden the repertoire of active compounds and elucidate the structural features responsible for their antibacterial activity, two novel derivatives of PYED-1 have been conceived herein.
View Article and Find Full Text PDFVenetoclax-induced degradation of VP8* lectin domain disrupts group A rotavirus replication.
Int J Biol Macromol
September 2025
Key Laboratory of Animal Vaccine Development, Ministry of Agriculture and Rural Affairs, College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China. Electronic address:
Group A Rotavirus (RVA) poses a significant health risk. Unfortunately, there are currently no the Food and Drug Administration (FDA) approved antiviral compounds available for treating RVA-induced diarrhea. The lectin-like domain of VP8* plays an important role in the RVA lifecycle.
View Article and Find Full Text PDFEnzyme-mediated nanoreactors with cascade metabolic modulation for enhanced chemo-chemodynamic combination therapy.
J Colloid Interface Sci
September 2025
School of Materials, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Electronic address:
Harnessing the significant buildup of lactic acid (LA) within the tumor microenvironment (TME) for metabolic manipulation presents a promising avenue for cancer treatment. Nevertheless, single-agent therapies often fail to address the complex and varying needs of TME heterogeneity, posing a substantial scientific hurdle in oncology. In this context, we employ asymmetric mesoporous silica nanoparticles (AMS NPs) as delivery vehicles, simultaneously loading them with zinc‑cobalt‑manganese ferrite nanoparticles (ZCMF NPs), lactate oxidase (LOX), and doxorubicin (DOX).
View Article and Find Full Text PDF